Inspiration Biopharmaceuticals names John Butler as ceo

Replaces Michael Griffith who takes position of cso

Inspiration Biopharmaceuticals, a US biopharmaceutical company focused on the development of treatments haemophilia, has appointed John Butler as ceo. He has replaced Michael Griffith, who has become chief scientific officer and remains company president.

Butler has joined Inspiration from Genzyme, which was acquired by Sanofi in April. While at Genzyme, he was most recently president of the company's rare genetic diseases business. He also led the company's renal, endocrinology, and cardiovascular businesses.

Prior to Genzyme, Butler held sales and marketing positions at Amgen and Hoffmann-La Roche.

You may also like

Manufacturing

CMC Biologics and Inspiration agree supply of IB1001

For the treatment and prevention of bleeding in haemophilia B patients
Design & Build

Guardtech Group celebrates record 2025 with global cleanroom expansion

A landmark year sees mobile, modular and GMP cleanrooms delivered across healthcare, pharma and microelectronics
Pharmaceutical

Cytiva and Fida Biosystems unite to improve molecular insight for faster drug discovery

The collaboration will combine complementary and orthogonal approaches to simplify workflows and improve confidence in experimental results
Manufacturing

SeaBeLife partners with Unither Pharmaceuticals for ophthalmic drug production

The new partnership aims to produce clinical and commercial batches of ophthalmic formulation of SeaBeLife’s drug candidate SBL03 to treat degenerative disorders of the retina, such as dry age-related macular degeneration
Pharmaceutical

SGS achieves breakthrough in infectious disease research with launch of novel RSV A-strain

Derived from a 2015 circulating strain, SGS's novel RSV-A challenge agent offers a closer match to circulating RSV viruses than strains currently used in clinical research
Regulatory

AstraZeneca's New Drug Application for hypertension drug accepted under FDA Priority Review

Baxdrostat has had positive Phase III trial results and, if approved, could be the first aldosterone synthase inhibitor to receive regulatory authorisation
Pharmaceutical

Samsung Bioepis expands European biosimilar portfolio with OBODENCE and XBRYK launches

The products, targeting osteoporosis and bone-related complications in cancer, strengthen access to affordable care and expand the company’s direct sales footprint across endocrinology and oncology
Subscribe now